

## Company Summary

Palleon Pharmaceuticals is a clinical-stage company pioneering drug development in glyco-immunology, a transformative field that may benefit patients with diseases driven by dysregulated glycans, including potentially the majority of cancer patients, as well as patients who have a wide array of inflammatory diseases.

Palleon has the team, platform technologies, intellectual property, and drug development strategies to overcome technical barriers unique to glycobiology to meaningfully advance and lead this novel field of drug development.



Palleon was co-founded by Dr. Carolyn Bertozzi, recipient of the 2022 Nobel Prize in Chemistry for the invention of bioorthogonal chemistry, a technology which enabled the company's foundational science.

## Glyco-Immunology

Glyco-immunology is an emerging field that focuses on how glycans - the sugar molecules that coat cell surfaces - regulate the immune system. This immune-regulatory axis can become dysfunctional with disease.

New research suggests that the upregulation of sialoglycans - complex sugar chains that terminate with a sialic acid and coat cell surfaces - suppresses the activation of the immune system in more than 50% of cancer patients. Both tumor cells and immune cells can become hypersialylated, contributing to immune evasion in cancer.

Dysregulated glycans are also linked to several inflammatory disorders including rheumatoid arthritis, idiopathic pulmonary fibrosis, and autoimmune vasculitis. Targeting sialoglycans and/or their receptors could have therapeutic potential in suppressing the immune system in these diseases.

## Differentiated Scientific Approach

Palleon's proprietary platforms overcome high technical barriers unique to glycobiology to de-risk clinical development by enabling drug discovery, patient selection, and indication prioritization.

- **EAGLE:** Enzyme therapy platform that restores antitumor immunity in cancer patients by stripping immunosuppressive sialoglycans from immune cells and cancer cells
- **HYDRA:** Translational platform that quantifies sialoglycan density to potentially select patients and de-risk clinical development
- **CONVERGENCE:** Comprehensive glycobiology discovery platform that targets Siglec receptors for the treatment of inflammatory diseases

## Lead Clinical-Stage Asset

E-602 is a first-in-class, glyco-immune checkpoint inhibitor which restores antitumor immunity by stripping immunosuppressive sialoglycans from hypersialylated tumor and immune cells. It is being evaluated in a Phase 1/2 clinical trial.



**Year of Founding:**  
2015



**Location:**  
266 Second Avenue,  
Waltham, MA 02451



**Employees:**  
38


### Leadership Team:

- Jim Broderick, M.D.  
*Chief Executive Officer & Founder*
- Li Peng, Ph.D.  
*Chief Scientific Officer*
- David Feltquate, M.D., Ph.D.  
*Chief Medical Officer*

## Pipeline & Programs

Palleon has a rich pipeline of first-in-class drug candidates in oncology and inflammatory diseases with multiple clinical readouts expected over the next 12-36 months.

- E-602: First-in-class lead oncology clinical candidate
  - GLIMMER-01: Phase 1/2a trial ongoing to assess safety, PK, PD, and antitumor activity of E-602 as a single agent and in combination with anti-PD-1
- E-434: First-in-class HER2-Sialidase to be evaluated in HER2-low and high patients with hypersialylated tumor types such as gastric, lung, colon, and breast
  - IND expected in 2024
  - Partnered with Shanghai Henlius Biotech for development and commercial rights in greater China
- Inflammatory disease program: Product nomination expected in early 2023; IND expected in 2024



### Investors:



### Contacts:

Media: [media@palleonpharma.com](mailto:media@palleonpharma.com)

Investors: [investors@palleonpharma.com](mailto:investors@palleonpharma.com)